EMA approves new antimalarial drug developed by Shinpoong

Published: 2012-02-22 06:57:00

Updated: 2012-02-22 06:57:00

Shinpoong Pharmaceutical Co. said Monday that the European Medicines Agency (EMA) approved a new artemisinin based combination therapy (ACT) Pyramax for treatment of malaria.

Co-developed by Switzerland based Medicines for Malaria Venture (MMV) and Shipoong, Pyramax is a fixed-dose combination...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK